Replies to post #607 on BioPharmX Corp fka BPMX

[Whos_Who]

Highlights,

Beating the competition,
“However, both doses are considerably lower than anything currently on the market as well as in development,”


Getting the share price back on track,
BPX-01 is also in a Phase 2 tolerability study for rosacea, and the company intends to share its pending results and plans for Phase 2/3 studies as soon as the end of May.